After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia

An emerging body of evidence demonstrates that defects in antileukemic effector cells in patients with acute myeloid leukemia (AML) can contribute to the development and/or persistence of the disease. In particular, immune suppressive regulatory T cells (Tregs) may contribute to this defective antil...

Full description

Saved in:
Bibliographic Details
Main Authors: Mario Delia, Paola Carluccio, Anna Mestice, Roberta Frappampina, Francesco Albano, Giorgina Specchia, Pellegrino Musto
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2020/2134647
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832554041427623936
author Mario Delia
Paola Carluccio
Anna Mestice
Roberta Frappampina
Francesco Albano
Giorgina Specchia
Pellegrino Musto
author_facet Mario Delia
Paola Carluccio
Anna Mestice
Roberta Frappampina
Francesco Albano
Giorgina Specchia
Pellegrino Musto
author_sort Mario Delia
collection DOAJ
description An emerging body of evidence demonstrates that defects in antileukemic effector cells in patients with acute myeloid leukemia (AML) can contribute to the development and/or persistence of the disease. In particular, immune suppressive regulatory T cells (Tregs) may contribute to this defective antileukemic immune response, being recruited by bone marrow leukemic cells to evade immune surveillance. We evaluated Tregs (CD4+/CD45RA-/CD25high/CD127low), performing multiparametric flow cytometry on freshly collected bone marrow aspirate (BMA), in addition to the usual molecular and cytogenetic work-up in newly diagnosed AML patients to look for any correlation between Tregs and the overall response rate (ORR). We studied 39 AML younger patients (<65 years), all treated with standard induction chemotherapy. ORR (complete remission (CR)+CR with incomplete hematologic recovery (CRi)) was documented in 21 out of 39 patients (54%); two partial responder patients were also recorded. Apart from the expected impact of the molecular-cytogenetic group (p=0.03) and the NPM mutation (p=0.05), diagnostic BMA Tregs did not show any correlation with ORR. However, although BMA Tregs did not differ in the study population after treatment, their counts significantly decreased in responder patients (p=0.039), while no difference was documented in nonresponder ones. This suggested that the removal of Treg cells is able to evoke and enhance anti-AML immune response. However, the role of BMA Tregs in mediating immune system-AML interactions in the diagnostic and posttreatment phase should be confirmed in a greater number of patients.
format Article
id doaj-art-c7f4f183bd5b4a728e87bee63be4029a
institution Kabale University
issn 2314-8861
2314-7156
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-c7f4f183bd5b4a728e87bee63be4029a2025-02-03T05:52:34ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/21346472134647After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid LeukemiaMario Delia0Paola Carluccio1Anna Mestice2Roberta Frappampina3Francesco Albano4Giorgina Specchia5Pellegrino Musto6Hematology and Bone Marrow Transplantation Unit-Azienda Ospedaliero-Universitaria Consorziale Policlinico, Department of Emergency and Organ Transplantation-University of Bari “Aldo Moro”, Bari, ItalyHematology and Bone Marrow Transplantation Unit-Azienda Ospedaliero-Universitaria Consorziale Policlinico, Department of Emergency and Organ Transplantation-University of Bari “Aldo Moro”, Bari, ItalyHematology and Bone Marrow Transplantation Unit-Azienda Ospedaliero-Universitaria Consorziale Policlinico, Department of Emergency and Organ Transplantation-University of Bari “Aldo Moro”, Bari, ItalyHematology and Bone Marrow Transplantation Unit-Azienda Ospedaliero-Universitaria Consorziale Policlinico, Department of Emergency and Organ Transplantation-University of Bari “Aldo Moro”, Bari, ItalyHematology and Bone Marrow Transplantation Unit-Azienda Ospedaliero-Universitaria Consorziale Policlinico, Department of Emergency and Organ Transplantation-University of Bari “Aldo Moro”, Bari, ItalyUniversity of Bari “Aldo Moro”, Bari, ItalyHematology and Bone Marrow Transplantation Unit-Azienda Ospedaliero-Universitaria Consorziale Policlinico, Department of Emergency and Organ Transplantation-University of Bari “Aldo Moro”, Bari, ItalyAn emerging body of evidence demonstrates that defects in antileukemic effector cells in patients with acute myeloid leukemia (AML) can contribute to the development and/or persistence of the disease. In particular, immune suppressive regulatory T cells (Tregs) may contribute to this defective antileukemic immune response, being recruited by bone marrow leukemic cells to evade immune surveillance. We evaluated Tregs (CD4+/CD45RA-/CD25high/CD127low), performing multiparametric flow cytometry on freshly collected bone marrow aspirate (BMA), in addition to the usual molecular and cytogenetic work-up in newly diagnosed AML patients to look for any correlation between Tregs and the overall response rate (ORR). We studied 39 AML younger patients (<65 years), all treated with standard induction chemotherapy. ORR (complete remission (CR)+CR with incomplete hematologic recovery (CRi)) was documented in 21 out of 39 patients (54%); two partial responder patients were also recorded. Apart from the expected impact of the molecular-cytogenetic group (p=0.03) and the NPM mutation (p=0.05), diagnostic BMA Tregs did not show any correlation with ORR. However, although BMA Tregs did not differ in the study population after treatment, their counts significantly decreased in responder patients (p=0.039), while no difference was documented in nonresponder ones. This suggested that the removal of Treg cells is able to evoke and enhance anti-AML immune response. However, the role of BMA Tregs in mediating immune system-AML interactions in the diagnostic and posttreatment phase should be confirmed in a greater number of patients.http://dx.doi.org/10.1155/2020/2134647
spellingShingle Mario Delia
Paola Carluccio
Anna Mestice
Roberta Frappampina
Francesco Albano
Giorgina Specchia
Pellegrino Musto
After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
Journal of Immunology Research
title After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
title_full After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
title_fullStr After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
title_full_unstemmed After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
title_short After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
title_sort after treatment decrease of bone marrow tregs and outcome in younger patients with newly diagnosed acute myeloid leukemia
url http://dx.doi.org/10.1155/2020/2134647
work_keys_str_mv AT mariodelia aftertreatmentdecreaseofbonemarrowtregsandoutcomeinyoungerpatientswithnewlydiagnosedacutemyeloidleukemia
AT paolacarluccio aftertreatmentdecreaseofbonemarrowtregsandoutcomeinyoungerpatientswithnewlydiagnosedacutemyeloidleukemia
AT annamestice aftertreatmentdecreaseofbonemarrowtregsandoutcomeinyoungerpatientswithnewlydiagnosedacutemyeloidleukemia
AT robertafrappampina aftertreatmentdecreaseofbonemarrowtregsandoutcomeinyoungerpatientswithnewlydiagnosedacutemyeloidleukemia
AT francescoalbano aftertreatmentdecreaseofbonemarrowtregsandoutcomeinyoungerpatientswithnewlydiagnosedacutemyeloidleukemia
AT giorginaspecchia aftertreatmentdecreaseofbonemarrowtregsandoutcomeinyoungerpatientswithnewlydiagnosedacutemyeloidleukemia
AT pellegrinomusto aftertreatmentdecreaseofbonemarrowtregsandoutcomeinyoungerpatientswithnewlydiagnosedacutemyeloidleukemia